Evaluation of the Biological Properties and the Enzymatic Stability of Glycosylated Luteinizing Hormone-Releasing Hormone Analogs

Overview

Journal AAPS J

Specialty Pharmacology

Date 2015 May 10

PMID 25956382

Authors

Shayli Varasteh Moradi

Pegah Varamini

Istvan Toth

Affiliations

Soon will be listed here.

Abstract

The enzymatic stability, antitumor activity, and gonadotropin stimulatory effects of glycosylated luteinizing hormone-releasing hormone (LHRH) analogs were investigated in this study. Conjugation of carbohydrate units, including lactose (Lac), glucose (GS), and galactose (Gal) to LHRH peptide protected the peptide from proteolytic degradation and increased the peptides' half-lives in human plasma, rat kidney membrane enzymes, and liver homogenate markedly. Among all seven modified analogs, compound 1 (Lac-[Q(1)][w(6)]LHRH) and compound 6 (GS(4)-[w(6)]LHRH) were stable in human plasma during 4 h of experiment. The half-lives of compounds 1 and 6 improved significantly in kidney membrane enzymes (from 3 min for LHRH to 68 and 103 min, respectively). The major cleavage sites for most of the glycosylated compounds were found to be at Trp(3)-Ser(4) and Ser(4)-Tyr(5) in compounds 1-5. Compound 6 was hydrolyzed at Ser(4)-Tyr(5) and the sugar conjugation site. The antiproliferative activity of the glycopeptides was evaluated on LHRH receptor-positive prostate cancer cells. The glycosylated LHRH derivatives had a significant growth inhibitory effect on the LNCaP cells after a 48-h treatment. It was demonstrated that compound 1 significantly increased the release of luteinizing hormone (LH) at 5 and 10 nM concentrations and compound 5 (GS-[Q(1)]LHRH) stimulated the release of follicle-stimulating hormone (FSH) at 5 nM concentration in dispersed rat pituitary cells (p < 0.05). In our studies, compound 1-bearing lactose and D-Trp was the most stable and active and is a promising candidate for future preclinical investigations in terms of in vitro biological activity and metabolic stability.

References

Katsila T, Siskos A, Tamvakopoulos C . Peptide and protein drugs: the study of their metabolism and catabolism by mass spectrometry. Mass Spectrom Rev. 2011; 31(1):110-33. DOI: 10.1002/mas.20340. View

Moradi S, Varamini P, Toth I . The transport and efflux of glycosylated luteinising hormone-releasing hormone analogues in caco-2 cell model: contributions of glucose transporters and efflux systems. J Pharm Sci. 2014; 103(10):3217-24. DOI: 10.1002/jps.24120. View

Bahk J, Hyun J, Lee H, Kim M, Cho G, Lee B . Expression of gonadotropin-releasing hormone (GnRH) and GnRH receptor mRNA in prostate cancer cells and effect of GnRH on the proliferation of prostate cancer cells. Urol Res. 1998; 26(4):259-64. DOI: 10.1007/s002400050054. View

Naor Z, Clayton R, Catt K . Characterization of gonadotropin-releasing hormone receptors in cultured rat pituitary cells. Endocrinology. 1980; 107(4):1144-52. DOI: 10.1210/endo-107-4-1144. View

Conn P, Crowley Jr W . Gonadotropin-releasing hormone and its analogs. Annu Rev Med. 1994; 45:391-405. DOI: 10.1146/annurev.med.45.1.391. View

Drouin J, Labrie F . Selective effect of androgens on LH and FSH release in anterior pituitary cells in culture. Endocrinology. 1976; 98(6):1528-34. DOI: 10.1210/endo-98-6-1528. View

Castellon E, Clementi M, Hitschfeld C, Sanchez C, Benitez D, Saenz L . Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma. Cancer Invest. 2006; 24(3):261-8. DOI: 10.1080/07357900600629591. View

Limonta P, Moretti R, Montagnani Marelli M, Motta M . The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans. Front Neuroendocrinol. 2004; 24(4):279-95. DOI: 10.1016/j.yfrne.2003.10.003. View

Walters K, Wegorzewska I, Chin Y, Parikh M, Wu T . Luteinizing hormone-releasing hormone I (LHRH-I) and its metabolite in peripheral tissues. Exp Biol Med (Maywood). 2008; 233(2):123-30. DOI: 10.3181/0707-MR-201. View

10.

Yao J, Zhou N, Lv Y, Zhang R, Liu K, Xue M . Metabolic stability of long-acting luteinizing hormone-releasing hormone antagonists. Amino Acids. 2012; 43(4):1557-66. DOI: 10.1007/s00726-012-1231-0. View

11.

Ravenna L, Salvatori L, Morrone S, Lubrano C, Cardillo M, Sciarra F . Effects of triptorelin, a gonadotropin-releasing hormone agonist, on the human prostatic cell lines PC3 and LNCaP. J Androl. 2000; 21(4):549-57. View

12.

Pappa E, Zompra A, Spyranti Z, Diamantopoulou Z, Pairas G, Lamari F . Enzymatic stability, solution structure, and antiproliferative effect on prostate cancer cells of leuprolide and new gonadotropin-releasing hormone peptide analogs. Biopolymers. 2010; 96(3):260-72. DOI: 10.1002/bip.21521. View

13.

Dondi D, Festuccia C, Piccolella M, Bologna M, Motta M . GnRH agonists and antagonists decrease the metastatic progression of human prostate cancer cell lines by inhibiting the plasminogen activator system. Oncol Rep. 2006; 15(2):393-400. DOI: 10.3892/or.15.2.393. View

14.

Varamini P, Mansfeld F, Blanchfield J, Wyse B, Smith M, Toth I . Synthesis and biological evaluation of an orally active glycosylated endomorphin-1. J Med Chem. 2012; 55(12):5859-67. DOI: 10.1021/jm300418d. View

15.

Bachhav Y, Kalia Y . Stability of triptorelin in the presence of dermis and epidermis. Int J Pharm. 2009; 378(1-2):149-51. DOI: 10.1016/j.ijpharm.2009.05.053. View

16.

Christie M, Simerska P, Jen F, Hussein W, Rawi M, Hartley-Tassell L . A drug delivery strategy: binding enkephalin to asialoglycoprotein receptor by enzymatic galactosylation. PLoS One. 2014; 9(4):e95024. PMC: 3988166. DOI: 10.1371/journal.pone.0095024. View

17.

Padula A . GnRH analogues--agonists and antagonists. Anim Reprod Sci. 2005; 88(1-2):115-26. DOI: 10.1016/j.anireprosci.2005.05.005. View

18.

Sealfon S, Weinstein H, Millar R . Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr Rev. 1997; 18(2):180-205. DOI: 10.1210/edrv.18.2.0295. View

19.

Tomar P, Jain N, Agarwal G, Dixit V . Goserelin loaded nanoparticles inhibit growth and induce apoptosis in human prostate cancer cell lines. Drug Deliv Transl Res. 2015; 2(4):265-71. DOI: 10.1007/s13346-012-0082-2. View

20.

Limonta P, Montagnani Marelli M, Moretti R . LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin Investig Drugs. 2001; 10(4):709-20. DOI: 10.1517/13543784.10.4.709. View